Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
News|Articles|March 15, 2021
- Pharmaceutical Technology-03-15-2021
- Volume 2021 eBook
- Issue 1
Resources, Guidelines, and Guidance Documents Directory
Advertisement
Find links to pertinent regulatory and standard setting resources, guidance documents, and guidelines.
Articles in this issue
over 5 years ago
It Takes a Bio/Pharma Villageover 5 years ago
Managing the Risk of Nitrosamine Impuritiesover 5 years ago
Collaborative Efforts Address Key Data Integrity Challengesover 5 years ago
Can FDA Reinvent Inspectionsover 5 years ago
FDA 2021 Guidance Agenda Sees Focus on Genericsover 5 years ago
A Real-World Approach to Evaluating Cleanroom Garmentsover 5 years ago
Regulatory and Standard Setting Organizations DirectoryAdvertisement
Related to this article
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Advertisement
Advertisement